Molecular structure of Zanamivir sesquihydrate, CAS Number: 139110-80-8� (anhydrous)
Zanamivir sesquihydrate (CAS 139110-80-8 (anhydrous))
Application:
Zanamivir sesquihydrate is a neuraminidase inhibitor
CAS Number:
139110-80-8 (anhydrous)
Molecular Weight:
332.31 (anhydrous basis)
Molecular Formula:
C12H20N4O7•3/2H2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Zanamivir sesquihydrate inhibits the activity of neuraminidase enzymes, which are necessary for the release of new viral particles from infected cells. By binding to the active site of neuraminidase, it prevents the cleavage of sialic acid residues on the surface of host cells and viral particles. This inhibition blocks the release of new viral particles from infected cells, thereby reducing the spread of the virus within the host. Zanamivir sesquihydrate′s mechanism of action involves disrupting the enzymatic activity of neuraminidase, thereby interfering with the replication and spread of certain viruses.
Zanamivir sesquihydrate (CAS 139110-80-8 (anhydrous)) References
- Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. | Satoh, K., et al. 2007. Biol Pharm Bull. 30: 1816-8. PMID: 17827748
- A novel screening method for influenza patients using a newly developed non-contact screening system. | Matsui, T., et al. 2010. J Infect. 60: 271-7. PMID: 20138082
- Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). | Takanashi, J., et al. 2010. J Neurol Sci. 292: 24-7. PMID: 20236662
- A case of hemorrhagic colitis after influenza A infection. | Okayama, S., et al. 2011. J Microbiol Immunol Infect. 44: 480-3. PMID: 21724476
- Influenza-associated monophasic neuromyelitis optica. | Nakamura, Y., et al. 2011. Intern Med. 50: 1605-9. PMID: 21804290
- Late delirious behavior with 2009 H1N1 influenza: mild autoimmune-mediated encephalitis? | Takanashi, J., et al. 2012. Pediatrics. 129: e1068-71. PMID: 22412029
- Treatment of pandemic influenza A (H1N1) 2009-associated encephalopathy in children. | Kawashima, H., et al. 2012. Scand J Infect Dis. 44: 941-7. PMID: 22830454
- Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection. | Mizuno, T., et al. 2014. PLoS One. 9: e92601. PMID: 24699254
- A New Influenza-Tracking Smartphone App (Flu-Report) Based on a Self-Administered Questionnaire: Cross-Sectional Study. | Fujibayashi, K., et al. 2018. JMIR Mhealth Uhealth. 6: e136. PMID: 29875082
- Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. | Fukao, K., et al. 2019. J Antimicrob Chemother. 74: 654-662. PMID: 30476172
- In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018-19 season: Comparison with the 2010-11 to 2017-18 seasons. | Ikematsu, H., et al. 2020. J Infect Chemother. 26: 775-779. PMID: 32249161
- Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza. | Slain, D. 2021. Ann Pharmacother. 55: 760-771. PMID: 33016090
- Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance. | Wakabayashi, T., et al. 2022. Curr Rev Clin Exp Pharmacol. 17: 144-148. PMID: 33588740
- Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season. | Tani, N., et al. 2022. J Infect. 84: 151-157. PMID: 34861350
Inhibitor of:
Neu.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zanamivir sesquihydrate, 5 mg | sc-358987 | 5 mg | $39.00 | |||
Zanamivir sesquihydrate, 25 mg | sc-358987A | 25 mg | $128.00 |